Scientists and clinicians are changing the way they look at asthma, evaluating whether the disease is driven not only by excessive inflammation but also by a fundamental failure to properly resolve it. The comprehensive paper, “Integrated Pro-Resolving Mechanisms: A New Dimension for Optimizing Anti-Inflammatory Therapy in Asthma — A Review of Impaired Inflammation Resolution in Airway Remodeling,” highlights how impaired “pro‑resolving” biological pathways may underlie persistent airway damage and explain why some patients continue to worsen despite aggressive anti‑inflammatory treatment. The research was published in Frontiers.
For decades, asthma therapy has focused on suppressing inflammation using inhaled corticosteroids (ICS), long‑acting bronchodilators and biologic drugs, according to the paper’s research team. Although these treatments reduce symptoms and exacerbations, many patients — especially those with severe or refractory asthma — continue to experience progressive airway remodeling and lung function decline, they wrote. Their new research argues that this gap stems from a neglected process: active resolution of inflammation.
Inflammation resolution is not passive, the researchers wrote. It is an active, programmed biological process designed to terminate inflammation, clear dying cells and restore tissue structure. When this process fails, inflammation may quiet temporarily but never fully ends — allowing structural damage to accumulate.
According to researchers, specialized pro‑resolving mediators (SPMs) — lipid molecules derived from fatty acids — and efferocytosis — the process by which macrophages clear apoptotic immune cells — are central to inflammation resolution. Together, these mechanisms form a self‑reinforcing loop that shuts down inflammation and initiates repair, they said.
The research compiled evidence from human studies, animal models and laboratory experiments that demonstrate the following asthma findings:
- Levels of SPMs, such as lipoxin A4 and resolvins, are reduced.
- Receptor signaling for these mediators is weakened.
- Macrophages show impaired ability to clear dying eosinophils and neutrophils.
This failure triggers a damaging cascade that researchers termed, “SPM deficiency → impaired efferocytosis → secondary necrosis → structural airway damage.”
Further detailing the process, the paper suggests that resolution defects appear most pronounced in severe and refractory asthma, early‑onset disease with airway remodeling and inflammatory phenotypes marked by high eosinophils or mixed granulocytes. In these patients, standard anti‑inflammatory therapies may reduce visible inflammation but leave the underlying resolution failure uncorrected — allowing airway thickening, fibrosis and irreversible lung impairment to progress, the authors noted.
Citing other studies to support their findings, researchers said that even under high‑dose ICS, some patients have persistently low SPM levels, which correlate with steroid resistance, frequent exacerbations and declining lung function.
Researchers suggested that measuring inflammation resolution capacity could transform asthma management. Potential biomarkers include:
- SPM profiles in blood or airway samples
- Damage‑associated molecular patterns (DAMPs) released during secondary necrosis
- Phagocytic indices reflecting macrophage efferocytosis efficiency
Used together, they said, these markers could help identify patients at risk for airway remodeling despite good symptom control, offering information that traditional markers like eosinophil counts or FeNO cannot provide.
The paper outlined several emerging therapeutic strategies aimed at restoring resolution rather than suppressing inflammation, including:
- Exogenous SPMs or stable analogs to replace missing pro‑resolving signals
- Drugs that boost SPM generation or receptor signaling
- Efferocytosis‑enhancing therapies that improve macrophage clearance of dying cells
Instead of replacing current treatments, the authors argued these approaches could synergize with ICS and biologics, potentially achieving true disease modification rather than temporary control.
Finally, despite promising evidence, researchers said major gaps remain. Most human studies are cross‑sectional, biomarker detection is technically challenging and pro‑resolving therapies have yet to be tested in large, randomized trials, they noted. Regulatory, manufacturing and reimbursement hurdles also loom large.
